Masters J - Search Results

1

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MK. James ND, et al. Among authors: masters j. BJU Int. 2009 Feb;103(4):464-9. doi: 10.1111/j.1464-410X.2008.08034.x. Epub 2008 Oct 8. BJU Int. 2009. PMID: 18990168 Clinical Trial.

2

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MK. James ND, et al. Among authors: masters j. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):577-81. doi: 10.1016/j.clon.2008.07.002. Epub 2008 Aug 29. Clin Oncol (R Coll Radiol). 2008. PMID: 18760574 No abstract available.

3

Stem cells in regenerative urology of the bladder.

Yamamoto H, Shah S, Masters JR, Popert RJ, Dasgupta P. Yamamoto H, et al. Among authors: masters jr. BJU Int. 2009 Nov;104(9):1183-4. doi: 10.1111/j.1464-410X.2009.08734.x. Epub 2009 Aug 12. BJU Int. 2009. PMID: 19678817 No abstract available.

4

Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin.

Popert RJ, Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR. Popert RJ, et al. Among authors: masters jr. Br J Urol. 1994 Aug;74(2):195-9. doi: 10.1111/j.1464-410x.1994.tb16585.x. Br J Urol. 1994. PMID: 7921938 Clinical Trial.

5

Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Popert RJ, Masters JR, Coptcoat M, Zupi G. Popert RJ, et al. Among authors: masters jr. Urol Res. 1995;22(6):367-72. doi: 10.1007/BF00296877. Urol Res. 1995. PMID: 7740656

6

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry. Birtle AJ, et al. Among authors: masters jr. BJU Int. 2005 Aug;96(3):303-7. doi: 10.1111/j.1464-410X.2005.05619.x. BJU Int. 2005. PMID: 16042718

7

Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes.

Davies SL, Popert R, Coptcoat M, Hickson ID, Masters JR. Davies SL, et al. Among authors: masters jr. Int J Cancer. 1996 Jan 3;65(1):63-6. doi: 10.1002/(SICI)1097-0215(19960103)65:1<63::AID-IJC11>3.0.CO;2-J. Int J Cancer. 1996. PMID: 8543398 Free article. Clinical Trial.

8

Can p53 staining be used to identify patients with aggressive superficial bladder cancer?

Masters JR, Vani UD, Grigor KM, Griffiths GO, Crook A, Parmar MK, Knowles MA; MRC Superficial Bladder Cancer Group Mitomycin-C Trial Collaborators. Masters JR, et al. J Pathol. 2003 May;200(1):74-81. doi: 10.1002/path.1293. J Pathol. 2003. PMID: 12692844 Clinical Trial.

9

Intravesical chemotherapy with epirubicin: a dose response study.

Masters JR, Popert RJ, Thompson PM, Gibson D, Coptcoat MJ, Parmar MK. Masters JR, et al. J Urol. 1999 May;161(5):1490-3. J Urol. 1999. PMID: 10210379 Clinical Trial.

10

Cancer stem cells.

Masters JR, Foley CL, Bisson I, Ahmed A. Masters JR, et al. BJU Int. 2003 Nov;92(7):661-2. doi: 10.1046/j.1464-410x.2003.04481.x. BJU Int. 2003. PMID: 14616438 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

552 results

Search Page